Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

BioVex Moves To U.S. For IPO Shot, Better Facilities

June 8, 2005

BioVex Moves To U.S. For IPO Shot, Better Facilities

June 8, 2005

Prolysis Gets $9.9M, Aims For Clinic By End Of 2006

June 1, 2005

Ardana Reports Positive Data In Teverelix LA Phase IIa Trial

June 1, 2005

Animal Testing Ethics Report Reaches No Solid Solution

June 1, 2005

Animal Testing Ethics Report Reaches No Solid Solution

June 1, 2005

Prolysis Gets $9.9M, Aims For Clinic By End Of 2006

June 1, 2005

Ardana Reports Positive Data In Teverelix LA Phase IIa Trial

June 1, 2005

Moving Fast, Astex Cleared For Clinical Trial Of AT 7519

May 25, 2005

ProStrakan Wants £50M IPO In Tough UK Public Market

May 25, 2005

View All Articles by Nuala Moran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...